Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALC NASDAQ:RVPH NASDAQ:SHPH NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$0.82+30.3%$0.72$0.46▼$7.20$9.89M0.973.23 million shs2.92 million shsRVPHReviva Pharmaceuticals$0.67+11.8%$0.66$0.26▼$17.20$7.87M0.56494,487 shs25,841 shsSHPHShuttle Pharmaceuticals$4.02+6.3%$6.34$3.16▼$55.90$2.56M0.18732,469 shs31.51 million shsTRAWTraws Pharma$0.83-0.6%$1.35$0.64▼$3.27$8.45M1.45555,218 shs129,186 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica+30.29%+8.01%+9.58%+43.39%-48.03%RVPHReviva Pharmaceuticals+11.80%+9.97%+75.19%-9.55%-95.61%SHPHShuttle Pharmaceuticals+6.35%+16.18%-22.66%-39.39%-88.61%TRAWTraws Pharma-0.60%-2.74%-45.95%-53.01%-41.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$0.82+30.3%$0.72$0.46▼$7.20$9.89M0.973.23 million shs2.92 million shsRVPHReviva Pharmaceuticals$0.67+11.8%$0.66$0.26▼$17.20$7.87M0.56494,487 shs25,841 shsSHPHShuttle Pharmaceuticals$4.02+6.3%$6.34$3.16▼$55.90$2.56M0.18732,469 shs31.51 million shsTRAWTraws Pharma$0.83-0.6%$1.35$0.64▼$3.27$8.45M1.45555,218 shs129,186 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica+30.29%+8.01%+9.58%+43.39%-48.03%RVPHReviva Pharmaceuticals+11.80%+9.97%+75.19%-9.55%-95.61%SHPHShuttle Pharmaceuticals+6.35%+16.18%-22.66%-39.39%-88.61%TRAWTraws Pharma-0.60%-2.74%-45.95%-53.01%-41.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 2.00Hold$10.001,125.64% UpsideRVPHReviva Pharmaceuticals 2.50Moderate Buy$66.679,838.38% UpsideSHPHShuttle Pharmaceuticals 1.00SellN/AN/ATRAWTraws Pharma 1.60Reduce$1.0020.92% UpsideCurrent Analyst Ratings BreakdownLatest SHPH, CALC, RVPH, and TRAW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Negative$1.006/18/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$1.006/15/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/15/2026TRAWTraws Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral6/15/2026TRAWTraws Pharma LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/1/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/29/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)5/20/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/18/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/15/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/4/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A($0.46) per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$1.48 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$11.14 per shareN/ATRAWTraws Pharma$2.79M3.01$0.76 per share1.09($0.07) per share-11.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)RVPHReviva Pharmaceuticals-$19.86M-$4.06N/AN/AN/AN/A-391.58%-119.08%8/13/2026 (Estimated)SHPHShuttle Pharmaceuticals-$11.72M-$47.70N/AN/AN/AN/A-408.34%-138.15%N/ATRAWTraws Pharma$9.17M-$1.69N/AN/AN/AN/A-913.18%-133.88%8/13/2026 (Estimated)Latest SHPH, CALC, RVPH, and TRAW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q4 2025TRAWTraws Pharma-$0.92-$0.53+$0.39-$0.53$2.72 millionN/A5/14/2026Q1 2026RVPHReviva Pharmaceuticals-$0.3550-$0.46-$0.1050-$0.46N/AN/A4/15/2026Q4 2025TRAWTraws Pharma-$1.2238-$0.71+$0.5138-$0.71$0.06 millionN/A3/31/2026Q4 2025SHPHShuttle PharmaceuticalsN/A$0.60N/A$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedicaN/A1.611.61RVPHReviva PharmaceuticalsN/A2.082.08SHPHShuttle PharmaceuticalsN/A0.300.30TRAWTraws PharmaN/A0.430.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/ARVPHReviva Pharmaceuticals63.18%SHPHShuttle Pharmaceuticals4.58%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%RVPHReviva Pharmaceuticals8.90%SHPHShuttle Pharmaceuticals12.60%TRAWTraws Pharma7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3015.80 million9.23 millionNo DataRVPHReviva Pharmaceuticals513.11 million11.67 millionOptionableSHPHShuttle Pharmaceuticals5637,000557,000Not OptionableTRAWTraws Pharma1710.16 million9.39 millionNo DataSHPH, CALC, RVPH, and TRAW HeadlinesRecent News About These CompaniesTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramJune 22, 2026 | globenewswire.comQ2 EPS Estimates for Traws Pharma Lifted by HC WainwrightJune 22, 2026 | americanbankingnews.comBrokerages Set Traws Pharma, Inc. (NASDAQ:TRAW) Target Price at $8.00June 20, 2026 | americanbankingnews.comOutlook for Bucks County biotech take another hit with second setback for flu drugJune 15, 2026 | bizjournals.comTraws defers midphase flu study after negative regulatory reviewJune 15, 2026 | fiercebiotech.comFMicron, Nebius surge premarket; Traws Pharma tumblesJune 15, 2026 | finance.yahoo.comTraws Pharma shares slide after UK regulator postpones influenza studyJune 15, 2026 | msn.comWhy did TRAW stock slump 28% after hours?June 13, 2026 | msn.comTraws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory ReviewJune 12, 2026 | quiverquant.comQTraws Pharma Provides Regulatory Update on Influenza ProgramJune 12, 2026 | globenewswire.comTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease OutbreaksMay 27, 2026 | globenewswire.comTraws Pharma Updates ATM Equity Offering Prospectus SupplementsMay 26, 2026 | tipranks.comTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsMay 15, 2026 | globenewswire.comTraws Pops on Hantavirus ResearchMay 9, 2026 | baystreet.caA hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gainsMay 9, 2026 | msn.comTraws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship OutbreakMay 8, 2026 | benzinga.comTraws Pharma Advances Development of Clinical Candidates for Hantavirus TreatmentMay 8, 2026 | quiverquant.comQTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsMay 8, 2026 | globenewswire.comTraws Pharma (TRAW) price target decreased by 24.14% to 5.61April 29, 2026 | msn.comTraws Pharma (NASDAQ:TRAW) Major Shareholder Purchases $998,207.43 in StockApril 29, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSHPH, CALC, RVPH, and TRAW Company DescriptionsCalciMedica NASDAQ:CALC$0.82 +0.19 (+30.29%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.77 -0.05 (-5.75%) As of 06/26/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Reviva Pharmaceuticals NASDAQ:RVPH$0.67 +0.07 (+11.80%) As of 06/26/2026 03:22 PM EasternReviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Shuttle Pharmaceuticals NASDAQ:SHPH$4.02 +0.24 (+6.35%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$3.53 -0.49 (-12.19%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.Traws Pharma NASDAQ:TRAW$0.83 -0.01 (-0.60%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.83 +0.00 (+0.36%) As of 06/26/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
